GSK and Ionis unveiled additional clinical data supporting bepirovirsen, a chronic hepatitis B therapy being pursued with a goal of achieving a “functional cure” in a subset of patients. The companies highlighted results positioning the program for continued regulatory review across multiple jurisdictions, including the US. Separate from the initial topline framing, GSK later spelled out more detailed Phase 3 outcomes for bepirovirsen, describing functional cure in nearly one-fifth of treated patients across two late-stage trials. The updates add specificity to the response rates and sharpen the benchmark for what regulators may expect when weighing benefit in a chronic, difficult-to-clear infection. Analysts cited in the reporting characterized the data as validation of a potentially large commercial runway if efficacy holds up in follow-on analyses. For biotech operators, the key takeaway is that hepatitis B antiviral development is moving from viral suppression toward cure-oriented endpoints with measurable responder rates. Next steps hinge on continued submissions and regulator interaction, with the program’s ability to reproduce “functional cure” signals across populations and endpoints remaining the central risk.